You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 579-A Targeting the NANOG-CRY1 axis sensitizes immunotherapy-refractory tumors and enhances efficacy of T cell-based immunotherapy by reinvigorating the anti-tumor immunity cycle

Article metrics

Article menu

Download PDFPDF

Regular Abstracts – Part 2
Checkpoint Blockade Therapy
579-A Targeting the NANOG-CRY1 axis sensitizes immunotherapy-refractory tumors and enhances efficacy of T cell-based immunotherapy by reinvigorating the anti-tumor immunity cycle

 

Online download statistics by month:

Online download statistics by month: October 2023 to June 2025

AbstractFullPdf
Oct 2023601
Nov 2023302034
Dec 202393050
Jan 20243000
Feb 20243208
Mar 202442013
Apr 202414014
May 20241205
Jun 20241200
Jul 2024803
Aug 20241203
Sep 20241002
Oct 2024407
Nov 20242504
Dec 20241608
Jan 20251005
Feb 2025807
Mar 2025009
Apr 2025109
May 2025007
Jun 2025005
Total6370194